Standard BioTools (LAB) Proxy filing summary

Executive summary

• The 2026 annual meeting will be held virtually on June 17, 2026, with voting on key proposals and director elections.

• Shareholders will vote on five main proposals, including director elections, executive compensation, auditor ratification, a new equity plan, and an amendment to the employee stock purchase plan.

• The company emphasizes sustainability, cost savings, and broad shareholder access through virtual meetings and electronic delivery of materials.

• Forward-looking statements highlight risks related to restructuring, M&A, cost savings, and market conditions.

Voting matters and shareholder proposals

• Election of three Class I Directors for terms expiring in 2029.

• Advisory vote on executive compensation (say-on-pay).

• Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.

• Approval of the 2026 Equity Incentive Plan.

• Approval of an amendment to the 2017 Employee Stock Purchase Plan to add 1,200,000 shares.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of seven members, majority independent, divided into three staggered classes.

• Nominees for Class I Directors: Michael Egholm, Ph.D., Thomas Carey, and Eli Casdin.

• Board committees: Audit, Human Capital, and Nominating and Corporate Governance, all with independent members.

• Board leadership is separated between an independent Chairperson and CEO.

• Policies include director tenure limits, overboarding restrictions, and robust stockholder engagement.